Home Online Features Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn's Perianal Fistulas
Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn’s Perianal Fistulas
Hand-out
Press Releases
February 27, 2025

Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn’s Perianal Fistulas

By Avobis Bio

– Only implantable cell therapy for Crohn's perianal fistulas with FDA IND clearance and Fast Track designation –

bradford

The Bradford Era

email
Local & Social